J&J Stock Rally Has More Room to Run, UBS and Cramer Agree
Johnson & Johnson shares are pushing toward record highs, with UBS and Jim Cramer both seeing further upside ahead.
Johnson & Johnson stock is on a tear toward record highs, and two prominent voices on Wall Street say the rally is far from over. Both UBS analysts and CNBC's Jim Cramer have independently signaled that J&J shares still carry meaningful upside, lending institutional and retail credibility to the bullish case.
Cramer's alignment with UBS is notable because it reflects a rare convergence between a major investment bank's research desk and one of television's most-watched market commentators. When institutional analysis and high-profile media voices echo the same thesis, it often amplifies investor attention and can draw fresh capital into a stock that is already outperforming.
Read more Apple Stock Diverges From Tech Peers at 20-Year Extreme →
Johnson & Johnson, one of the most widely held blue-chip names in the healthcare sector, has long been viewed as a defensive anchor in diversified portfolios. A sustained run toward record territory suggests investors are growing more confident in the company's fundamentals, pipeline, and ability to navigate ongoing legal and macroeconomic headwinds that have weighed on the stock in prior quarters.
The convergence of bullish signals raises the question of what specific catalysts — whether earnings momentum, pharmaceutical pipeline developments, or broader sector rotation into healthcare — are powering this move. Analysts watching the name will likely scrutinize upcoming quarterly results and any guidance updates as critical checkpoints for whether the record-high thesis holds.
Continue reading at US Top News and Analysis.
